Clinical Trials · NCT01252693
International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc
- Enrollment
- 203
- Start date
- Nov 2010
- Locations
- 3 sites, United States
- Primary endpoint
- To assess the percentage of patients with testosterone <=0.5ng/mL.